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Unraveling the identity of FoxP3+ 
regulatory t cells in Granulomatosis 
with polyangiitis patients
tom D. Y. Reijnders  1, Coen A. stegeman2, M. G. Huitema1, Abraham Rutgers  1, 
peter Heeringa  3 & Wayel H. Abdulahad1,3
Human CD4+FoxP3+t-cells are heterogeneous in function and include not only suppressive cells 
(Tregs), but also effector cells that transiently express FoxP3 upon activation. previous studies in 
Granulomatosis with polyangiitis (GpA-)patients have demonstrated an increase in FoxP3+t-cells 
with impaired suppressive capacity and an increase in Th17 cells. We hypothesized that the increase in 
FoxP3+T-cells results from an increase in non-suppressive effector-like cells. The frequency of circulating 
CD4+FoxP3+T-cell subsets were determined by flow cytometry in 46 GPA-patients in remission and 
22 matched healthy controls (HCs). Expression levels of FoxP3 and CD45RO were used to distinguish 
between CD45RO− FoxP3low resting Tregs (rTreg), CD45RO+FoxP3high activated tregs (atreg) and 
CD45RO+FoxP3low proinflammatory non-suppressive T-cells (nonTreg). Intracellular expression of IFNγ, 
IL-17, and IL-21 was compared within these subsets. We found a significant increase in the frequency 
of nonTreg cells in GPA-patients as compared with HCs. Importantly, within the nonTreg subset, 
antineutrophil cytoplasmic autoantibody (ANCA-)positive patients demonstrated a significantly 
higher percentage of IL-17+ and IL-21+ cells when compared with ANCA-negative patients and 
HCs. Moreover, expanded nonTregs from ANCA-positive patients induced excessive proliferation of 
responder cells in vitro and exhibited higher IL-21 production. Production of IL-17 and IL-21 in non-
suppressive FoxP3+T-cells may point toward a pathogenic role in ANCA formation.
Granulomatosis with Polyangiitis (GPA) is a necrotizing granulomatous autoimmune small-vessel vasculitis 
distinguished by circulating antineutrophil cytoplasmic autoantibodies (ANCA) that predominantly target pro-
teinase 3 (PR3)1. ANCA-induced neutrophil-mediated tissue damage has classically been deemed the primary 
pathogenic mechanism2. However, accumulating evidence points towards an essential role for T cells in disease 
expression and progression: effector T cells are found in biopsies of inflamed renal and granulomatous tissue3,4; 
ANCAs are class-switched autoantibodies and therefore necessitate T cell help5; increased serum markers of T cell 
activation correlate with disease activity6,7; and peripheral blood homeostasis of CD4+ T cells is disturbed with 
the persistent expansion of effector memory cells during remission8,9.
Autoimmunity in GPA implies a critical defect in the tolerance to self-antigens. Human regulatory T cells 
(Tregs) are key mediators of peripheral tolerance that can actively inhibit inflammation and suppress effector 
T cell function and proliferation. Tregs are characterized by the presence of FoxP3, a transcription factor that is 
critical to their development and function10. Our group previously demonstrated that GPA-patients in disease 
remission exhibit a marked increase in circulating T cells expressing FoxP311. Yet this increase failed to confer 
enhanced suppression, as these cells were functionally defective11, a finding since corroborated by others12,13.
FoxP3 has been considered a master regulator of Treg development and function: unique to the Treg line-
age14–16. However, effector T cells may transiently express FoxP3 upon activation, without acquiring suppres-
sor function17. Distinguishing suppressive and non-suppressive FoxP3+ T cells has proved challenging, due to 
the ambiguity of conventional markers10. Miyara et al. classified FoxP3+ T cells by the level of FoxP3 expres-
sion and whether these cells possessed a naïve or memory phenotype and found three distinct populations: 
CD45RO− FoxP3low resting Tregs (rTreg), CD45RO+ FoxP3high activated Tregs (aTreg) and CD45RO+ FoxP3low 
1Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center 
Groningen, Groningen, The Netherlands. 2Department of Internal Medicine, Division of Nephrology, University 
of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 3Department of Pathology and 
Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 
Correspondence and requests for materials should be addressed to W.H.A. (email: w.abdulahad@umcg.nl)
Received: 8 January 2018
Accepted: 21 May 2019
Published: xx xx xxxx
OPEN
2Scientific RepoRts |          (2019) 9:8273  | https://doi.org/10.1038/s41598-019-44636-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
proinflammatory cytokine secreting non-suppressive T cells (nonTreg)18. Furthermore, even suppressive Tregs 
may acquire the ability to produce effector cytokines (such as IL-17) upon activation in the context of a proin-
flammatory milieu19–21.
In addition to FoxP3+ T cells, our group reported increased frequencies of circulating T cells producing 
IL-1722, as well as IL-2123, in GPA-patients.
Based on these observations, we hypothesized that the overabundance of functionally defective FoxP3+ T 
cells results from an expansion of effector-like cells that readily produce proinflammatory cytokines despite 
expression of FoxP3. Elucidating the functional and phenotypical characteristics of FoxP3+ T cells in GPA may 
form a next step in the search for novel monitoring tools and possible directed therapies.
Results
the increase in FoxP3+ t cells in GpA is predominantly due to an expansion of nontreg cells. 
We first analyzed the percentages of total FoxP3+ cells within CD4+ T cells in peripheral blood of GPA-patients 
in remission and matched healthy controls (HCs). In line with our previously published data11, the frequency of 
circulating FoxP3+ T cells in GPA-patients was significantly increased when compared with HCs (Fig. 1b). No 
differences were found between patients who were currently ANCA-negative or ANCA-positive (Fig. 1c), patients 
with localized or generalized disease (Fig. 1d), or untreated patients and those receiving maintenance therapy 
(Fig. 1e).
To evaluate the identity of the FoxP3+ T cells, we subdivided these cells according to the three populations 
described by Miyara et al.18 (Fig. 1a). Strikingly, we found that the increase in FoxP3+ T cells in GPA-patients 
is largely caused by an increase in the nonTreg subset (Fig. 1b). When compared with HCs, the median propor-
tion of nonTreg cells within CD4+ T cells was about twice as large in ANCA-positive patients (p = 0.0002) and 
ANCA-negative patients (p < 0.0001; Fig. 1c). The percentages of the rTreg subset were comparable between 
ANCA-positive patients, ANCA-negative patients and HCs (Fig. 1c).
Whereas ANCA-positive and ANCA-negative patients did not differ in nonTregs and rTregs, ANCA-negative 
patients showed a significantly expanded population of aTregs when compared with both ANCA-positive 
patients and HCs (Fig. 1c). These data indicate that, in GPA-patients, an expansion of aTregs is accompanied by 
an absence of circulating ANCAs. As with total FoxP3+ T cells, no differences were found when comparing the 
three Treg subsets between patients based on disease localization or treatment status at the time of blood sam-
pling (Fig. 1d,e).
NonTreg cells from ANCA-positive patients produce more proinflammatory cytokines. Next, 
we determined the intracellular expression of the proinflammatory cytokines IL-17, IFNγ and IL-21 in the three 
FoxP3+ T cell subsets after in vitro activation of PBMCs by PMA and calcium ionophore. Representative flow 
cytometry plots can be found in Supplementary Fig. S1. As expected, the nonTreg subset contained the highest 
frequencies of proinflammatory cytokine producing cells (Fig. 2). Within the nonTreg subset, ANCA-positive 
patients produced significantly more IL-17 and IL-21 (Fig. 2a,c) – but not IFNγ (Fig. 2b) – than both 
ANCA-negative patients and HCs, underscoring a link between these two cytokines and circulating ANCAs. In 
similar fashion, aTregs from ANCA-positive patients produced more IFNγ, IL-17 and IL-21 than aTregs from 
ANCA-negative patients (Fig. 2a–c). The rTreg subset displayed no differences in cytokine expression between 
any of the groups.
In vitro expanded nonTreg cells from ANCA-positive patients induce responder T cell prolifer-
ation and produce more IL-21. We next assessed the suppressive capacities of the three Treg subsets in 
ANCA-positive GPA-patients and compared the results with those of matched HCs. We isolated and expanded 
the three Treg subsets in vitro and subsequently co-cultured them with autologous responder T cells (Tresp; 
CD4+  CD25−). We calculated suppression for each subset using Tresp proliferation. Although the limited sam-
ple size prevents drawing definitive conclusions, the results are intriguing nonetheless (Fig. 3). As expected, the 
overall suppressive capacity was reduced in GPA-patients (Fig. 3b). The nonTreg subset in HCs actually appeared 
to regain the ability to suppress after in vitro expansion. In stark contrast, the nonTreg subset in GPA-patients 
induced excessive proliferation of Tresp cells. Increased IL-21 production in these cells further underlines their 
effector-like phenotype (Fig. 3c). These preliminary data implicate the nonTreg subset in the exacerbation of 
cell-mediated inflammation in GPA-patients.
Discussion
Our results clarify the identity of the expanded FoxP3+ T cells in GPA-patients. The increase in FoxP3+ T cells 
can be attributed to an expansion of the cytokine producing effector non-suppressive Treg subset (nonTregs). In 
ANCA-positive patients, these cells produced more of the proinflammatory cytokines IL-17 and IL-21. Moreover, 
in vitro expanded nonTregs from ANCA-positive patients caused excessive proliferation of T effector cells and 
exhibited higher IL-21 production. Combined with their defective suppressor function, these observations indi-
cate a pathogenic role for FoxP3+ T cells in ANCA formation.
Our data reveal the identity of FoxP3+ T cells in GPA, but questions remain regarding their origins. Miyara 
and colleagues24 consider the non-suppressive subset to be derived from naïve CD4+ cells that transiently upreg-
ulate FoxP3 upon activation. An alternative explanation stems from the plasticity between Tregs and Th17 cells, 
two cell lineages presumed to originate from the same precursor25. IL-17+ FoxP3+ cells, which express the Th17 
transcription factor RORγt, can be generated in the presence Th17-inducing cytokines such as IL-1β, IL-6, IL-21 
and IL-2319–21. FoxP3 antagonizes RORγt function26 and high expression therefore appears protective against an 
IL-17 producing phenotype20. In contrast, the alternatively spliced isoform lacking exon 2 (FoxP3Δ2) fails to effect 
this inhibition26. Free et al. demonstrated an overrepresentation of FoxP3Δ2 in patients with ANCA-associated 
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vasculitis13. Collectively, we speculate that the IL-17+ FoxP3+ cells found here partially originate from cells with 
increased susceptibility to Th17 plasticity – expressing low levels of FoxP3 or predominantly expressing FoxP3Δ2. 
IL-17+ FoxP3+ T cells are present in inflammatory lesions in autoimmune diseases such as rheumatoid arthri-
tis27, psoriasis28 and inflammatory bowel disease29. As of yet, no subset of Tregs has been described that produce 
IL-21. Therefore, it is likely that the IL-21+ FoxP3+ cells found here represent activated effector memory cells.
Our group and others previously demonstrated skewing towards a Th17 phenotype in GPA22,30,31 and an 
expanded T effector memory population that persists during disease remission8,9. Our current finding is in line 
Figure 1. Percentages of circulating Treg subpopulations in GPA-patients and HCs. (a) Representative flow 
cytometry plots of CD45RO and FoxP3 expression on gated CD4+ T cells in freshly isolated PBMCs obtained 
from one HC (left) and one GPA-patient (right) for determining the frequencies of CD45RO− FoxP3low resting 
Tregs (rTreg), CD45RO+ FoxP3high activated Tregs (aTreg) and CD45RO+ FoxP3low proinflammatory cytokine 
secreting non-suppressive T cells (nonTreg). The percentages of circulating FoxP3+ CD4+ T cells and the 
percentages of the Treg subsets within CD4+ T cells were compared between: (b) HCs and GPA-patients; (c) 
HCs, ANCA-positive (ANCA+; ANCA titer higher than 1:20 at time of blood sampling) and ANCA-negative 
(ANCA−) GPA-patients; (d) HCs and GPA-patients with generalized (Gen.) or localized (Loc.) disease; (e) 
HCs and treated and untreated GPA-patients. Horizontal lines in the scatterplots represent the median. P-values 
were calculated using the nonparametric Mann-Whitney U-test.
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with these observations and suggests that the expanded non-suppressive FoxP3+ T cell subset with a memory 
phenotype may be an important source of proinflammatory cytokines. IL-17 is a critical player in autoimmun-
ity, partly through its effects on the innate immune system. Secretion of IL-17 drives the production of various 
chemokines that recruit neutrophils32 and stimulates macrophages to produce IL-1β and TNF-α33, two proin-
flammatory cytokines that prime neutrophils34. In GPA, primed neutrophils translocate PR3 to their cell mem-
brane. Subsequent interaction of PR3 with PR3-ANCA causes neutrophils to degranulate, followed by a sequence 
of proinflammatory events culminating in necrotizing vasculitis34. Thus, IL-17 likely plays a key initiating role in 
the pathogenesis of GPA.
In addition to IL-17, FoxP3+ T cells from ANCA-positive patients also produced more IL-21, which is in 
accordance with our previous data23. IL-21 induces pathogenic effector cells (mainly Th17) and causes them to 
expand35,36. Additionally, it may impair homeostasis and function of bona fide Tregs via suppression of FoxP3 and 
decreased availability of IL-236,37, or by making T effector cells refractory to suppression38. Importantly, IL-21 
stimulates (auto)antibody production, antibody class switching and it synergizes with B cell activating factor to 
promote plasma cell generation39,40. Accordingly, IL-21 significantly enhances in vitro PR3-ANCA generation in 
ANCA-positive GPA-patients23.
Furthermore, we found that ANCA- negative patients have higher frequencies of aTregs than ANCA-positive 
patients. It is conceivable that the expansion of this population results in suppression of ANCA formation, as 
Tregs may directly inhibit autoantibody production by B cells in autoimmune disease41. Conversely, the ele-
vated levels of IL-21 in ANCA positive patients may culminate in enhanced autoantibody production, as well as 
reduced levels of aTregs. While it is impossible to infer cause and effect from these data alone, it seems apparent 
that IL-21 plays a critical role in ANCA production and disturbances in Treg homeostasis in GPA.
The results of the suppression assay suggest that the expanded population of nonTregs in GPA-patients not 
only fail to suppress, but may even enhance effector T cell proliferation. The need for in vitro expansion of the 
small number of cells obtained from sorting may limit translation to the in vivo situation. The small sample size 
is another obvious limitation of this assay. Despite these caveats, the experimental design here is unprecedented 
and the results provide valuable insight into the consequential functional differences dividing the Treg subsets of 
GPA-patients and healthy controls.
Figure 2. Percentages of cytokine secreting Treg cells in GPA-patients and HCs. Proportion of rTreg, aTreg 
and nonTreg cells producing IL-17 (a), IFNγ (b) or IL-21 (c) in ANCA-positive (ANCA+; ANCA titer higher 
than 1:20 at time of blood sampling) GPA-patients (n = 9), ANCA-negative (ANCA−) GPA-patients (n = 10), 
and HCs (n = 12) Horizontal lines in the scatterplots represent the median. P-values were calculated using the 
nonparametric Mann-Whitney U-test.
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Our data demonstrate that the overabundance of circulating FoxP3+ T cells in GPA-patients predominantly 
results from an expansion of the non-suppressive nonTregs. Within this subset, ANCA-positive patients produced 
significantly more of the proinflammatory cytokines IL-17 and IL-21, pointing to their role in disease pathogen-
esis. Further research is needed to elucidate the origins of these cells – in particular whether the IL-17+ FoxP3+ 
cells represent inherent and/or microenvironmental susceptibility to Th17 plasticity – and to confirm their path-
ogenicity in GPA. Understanding the role of FoxP3+ T cells in GPA may pave the way for novel monitoring tools 
and possible therapeutic targets.
Figure 3. The suppressive capacity and cytokine pattern of in vitro expanded Treg subsets from ANCA-positive 
patients and HCs. Responder T (Tresp) cells were labeled with proliferation dye eFluor670 and stimulated 
to proliferate with anti-CD3/CD28 beads in the presence or absence of each in vitro expanded autologous 
Treg subset (rTreg, a Treg and nonTreg) separately in a 1:1 ratio. After 3 days, proliferation dye dilution was 
determined by flow cytometry and used to calculate suppression. (a) Representative Tresp cell proliferation 
dye dilution histograms for the different co-cultures. Each peak represents a successive generation of divided 
Tresp cells. (b) Bar charts comparing the percentage of suppression in each co-culture experiment between 
GPA-patients (n = 3) and HCs (n = 3). The bar represents the median and the whiskers represent the range. (c) 
Frequency of IL-17, IFNγ, and IL-21 production by in vitro expanded Treg subsets (rTreg, aTreg and nonTreg) 
from GPA-patients (n = 2) and HCs (n = 2).
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Methods
study population. 46 consecutive patients with GPA (Table 1) and 22 age- and sex-matched healthy controls 
(15 males, 7 females, mean age 52 years, range 20–79 years) were enrolled in this study. The main clinical and 
laboratory data of the patients are summarized in Table 1. The diagnosis of GPA was established according to the 
definitions of the Chapel Hill Consensus Conference42 and fulfilled the classification criteria of the American 
College of Rheumatology43 for GPA. Only patients without clinical signs and symptoms of active vasculitis and 
considered to be in complete remission, as indicated by the Birmingham vasculitis activity score (BVAS)44, were 
included in this study. According to these criteria, all GPA-patients were in remission at the time of sampling. 
Of the 46 patients, 32 were considered generalized-GPA that included renal involvement, and 14 patients were 
considered localized-GPA which is confined to the upper and/or lower respiratory tract. None of the patients and 
controls experienced an infection at the time of sampling. 32 patients were receiving maintenance therapy at time 
of sampling, as specified in Table 1. All patients and healthy individuals provided informed consent and the study 
was approved by the local medical ethics committee (METc2012/151). The patient selection criteria and defini-
tions described in this section are similar to those in our previous work on T cells in GPA to ensure consistency 
and facilitate comparisons between studies11,23.
Serum ANCA titer. ANCA titers were measured by indirect immunofluorescence (IIF) on ethanol-fixed 
human granulocytes according to the standard procedure as previously described45. ANCA titers higher than 
1:20 were considered positive. All included patients were ANCA-positive at initial diagnosis with specificity for 
proteinase-3 (PR3-ANCA).
Antibodies. The following conjugated anti-human antibodies were used in flow cytometry: Pacific Blue 
conjugated (PB) anti-CD3 (clone UCHT1), allophycocyanin (APC) or peridin-chlorophyll (PerCP) conju-
gated anti-CD4 (clone SK3), fluorescein isothiocyanate (FITC) or phycoerythrin-Cyanin7 (PE-Cy7) conjugated 
anti-CD45RO (clone UCHL1), and PerCP conjugated anti-CD8 (clone SK1). All antibodies were purchased from 
Becton-Dickinson (Amsterdam, The Netherlands). PE or APC conjugated anti-human FoxP3 (clone PCH101), 
Alexa Fluor700 conjugated anti-IFNγ (clone 4S.B3), Alexa Fluor488 conjugated anti-IL-17 (clone eBio64Dec17), 
and PE conjugated anti-IL21 (clone eBio3A3-N2) were obtained from eBioscience (San Diego, CA, USA). Isotype 
matched control antibodies of irrelevant specificity were purchased from Becton-Dickinson and eBioscience.
Isolation of peripheral blood mononuclear cells (PBMC). Isolation of PBMCs was performed as 
described previously11,23. Briefly, peripheral blood was obtained by venipuncture in heparinized tubes, and 
PBMC were immediately isolated by density-gradient centrifugation on Lymphoprep (Axis-Shield PoC AS, Oslo, 
Norway). Cells were washed two times in phosphate-buffered saline pH 7.2 (PBS), and resuspended at 1 × 107 
cells/mL in RPMI 1640 (Cambrex Bio Science, Verviers, Belgium) supplemented with 5% human pool serum and 
50 μg/ml gentamycin (Gibco, Scotland, UK).
Flow cytometry staining to determine the frequency of circulating Treg cell subsets. Foxp3 
staining was performed according to the manufacturer’s instructions (Foxp3-staining kit, eBioscience, ITK diag-
nostic BV, The Netherlands) as described previously11,23. Briefly, freshly isolated PBMC (1 × 106 cells in 100 μL) 
were immediately incubated with appropriate concentrations of FITC-anti-CD45RO, and PerCP-anti-CD4 for 
30 minutes at 4 °C in the dark, washed with cold PBS followed by fixation and permeabilization in Fix/Perm 
Characteristic Patients (n = 46)
Male/female 31/15
Age, mean (range) years 54 (20–78)
Localized/generalized GPA 14/32
Positive/negative for ANCA† 27/19






Prednisolone and azathioprine 9
Prednisolone and mycophenolate mofetil 5
Prednisolone and cyclophosphamide 4
Cyclosporine 1
Cotrimoxazole 2
Disease duration, mean (range) months 78 (5–266)
Table 1. Clinical and laboratory characteristics of the GPA-patients. ANCA Anti neutrophil cytoplasmic 
antibody, GPA Granulomatosis with polyangiitis. †ANCA titer higher than 1:20 at time of blood sampling. All 
included patients were ANCA-positive at initial diagnosis.
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buffer (eBioscience) for 45 minutes at 4 °C. Subsequently, cells were washed twice with cold 1X Permeabilization 
buffer (eBioscience). To block non-specific binding, normal rat serum was added for 10 minutes, followed by the 
addition of PE-conjugated rat anti-human-FoxP3. After incubation for 30 minutes at 4 °C, the cell suspension 
was washed twice with cold 1X Permeabilization buffer and four-color staining was immediately analyzed on 
FACS-Calibur (Becton & Dickinson). For all flow cytometry analyses, data were collected for 105 lymphocytes, 
gated by forward and side scatter, and plotted using Kaluza software package (Beckman Coulter, USA). CD4+ 
T cells were gated and the expression levels of FoxP3 and CD45RO were used for distinction between rTregs 
(CD45RO− FoxP3low), aTregs (CD45RO+ FoxP3high) and nonTregs (CD45RO+ FoxP3low) as shown in Fig. 2A 
and described by Miyara and colleagues18.
Stimulation assay and immunofluorescent intracellular staining for cytokines. Immediately 
after isolation, 1 × 106 PBMCs were resuspended in 400 μl RPMI1640 (Cambrex Bio Science, Verviers, Belgium), 
supplemented with 50 μg/ml gentamycin (Gibco, Paisley, Scotland, UK), and aliquoted into 5 ml polypropylene 
tubes (BD Biosciences, Amsterdam, The Netherlands). To determine the frequency of cytokine expressing Treg 
subsets, cells were stimulated for 16 h with 8 nM phorbol myristate acetate (PMA; Sigma-Aldrich, Steinheim, 
Germany) and 0.4 nM calcium ionophore (Ca-Io; Sigma-Aldrich) in the presence of 3 μM Brefeldin A. Brefeldin 
A was used to block intracellular transport mechanisms, thereby leading to an accumulation of cytokines in the 
cell. As a negative control, one sample remained without stimulation. Culture tubes were incubated at 37 °C, 5% 
CO2.
After stimulation, cells were washed in wash buffer (PBS, 5% fetal bovine serum (FBS)) and stained with 
PerCP-anti-CD8 (clone SK1, BD Biosciences, Amsterdam, The Netherlands) and APC-anti-CD3 (clone UCHT1, 
BD Biosciences), for 15 minutes at room temperature. Next, cells were washed, fixed, and permeabilized using the 
Foxp3-staining kit from eBioscience as mention before. After permeabilization, cells were stained intracellularly 
by adding APC-conjugated rat anti-human-FoxP3, Alexa Fluor 700-anti-IFNγ, Alexa Fluor 488-anti-IL-17, and 
PE-anti-IL-21 and incubated for 30 minutes at 4 °C. The cell suspension was washed and analyzed directly on 
LSR-II (Becton & Dickinson). Data were collected for 105 lymphocytes and plotted using Kaluza software pack-
age (Beckman Coulter, USA). Treg cell subsets were gated separately and the frequency of IFNγ or IL-17 or IL-21 
secreting cells were measured within each subset.
Cell sorting and in vitro expansion of treg cell subsets. Freshly isolated PBMCs from 3 
ANCA-positive GPA-patients and 3 age- and sex-matched HCs were stained with anti-CD4-eF450, anti-CD25-PE 
and anti-CD45RO-FITC, and sorted on a MoFlo-Astrios (Beckman Coulter) according to Miyara’s classification18 
into the following 4 populations: rTreg (CD4+CD25+CD45RO−), aTreg (CD4+CD25HighCD45RO+), non-Treg 
(CD4+CD25LowCD45RO−) and responder T cells (Tresp; CD4+CD25−) (Supplementary Fig. S2). Tresp cells were 
frozen in liquid nitrogen until use. The 3 other Tregs fractions were expanded in vitro for 2 weeks using anti-CD3/
CD28 Dynabeads (Thermo Fisher Scientific) and 200IU of IL-2 (Peprotech, Rocky Hill, USA) in RPMI1640 
(Lonza, Breda, The Netherlands) supplemented with 10% human pooled serum (Lonza) and 60 µg/ml gentam-
ycin sulfate (Lonza). Part of the 3 expanded Treg subsets was used in suppression assays (as described below) to 
determine their suppressive capacity, and another part was frozen and used later to assess cytokine production 
(as described above).
suppression Assay. Tresp cells were thawed, labeled with proliferation dye eFluor670 (eBioscience), stimu-
lated with anti-CD3/CD28 Dynabeads and cultured (2 × 104 cells/well) in a round-bottomed 96-well plate in the 
presence or absence of each autologous Treg subset (rTreg, aTreg and nonTreg) separately at a 1:1 ratio. After 3 
days of culture, cells were harvested, washed and stained with Zombie UV Fixable Viability dye (Biolegend) and 
analyzed on an LSR-II (Becton & Dickinson). Dead cells were excluded and Tresp cell proliferation was deter-
mined by following eFluor670 dilution using FCS-expressTM 6 software (De Novo Software, Glendale, CA). The 
percentage suppression of proliferation was calculated as follows:
=
−
×%Suppression %proliferation Tresp alone %proliferation Tresp in coculture with Treg
%proliferation Tresp alone
100%
statistical analysis. Data are presented as median unless stated otherwise. Comparison of median values 
between GPA-patients and healthy controls was assessed using nonparametric Mann-Whitney U-test, and differ-
ences were considered statistically significant at two-sided P-values less than 0.05.
ethics approval and consent to participate. All patients and healthy controls provided informed con-
sent before participating in the study. The study was approved by the Medical Ethics Committee of the University 
of Groningen/University Medical Center Groningen, The Netherlands (METc2012/151). All procedures were in 
accordance with the Declaration of Helsinki.
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on rea-
sonable request.
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